Researchers at Oncotarget have found a potential treatment for the third most deadly type of cancer in the world, colon cancer. While traditional treatments generally include chemotherapy and bowel resection, Oncotarget has found that by combining methlglyoxal (MG), a glucose metabolite, and other functions of the glyoxalase system tumor growth was suppressed. Check the journal at SCImago Journal & Country Rank. In previous studies of MG alone, the results of its effectiveness were lacking though did show some potential in colon and breast cancer cells by preventing mitochondrial respiration, essentially suffocating the cancer cells. While the full impact and even functionality of this discovery is still unknown, Oncotarget researchers are finding potential in treatments by combining them.
Oncotarget’s impact on cancer research isn’t limited to their own, they’re dedicated to ensuring that the community is able to access who and what they need in order to advance cancer research. During 2017’s Frontiers in Cancer Science held on November 6 through 8th in Singapore, Oncotarget awarded 4 grants to international researchers based on a broad variety of presentation topics including mesothelioma and renal cancer. These researchers were as follows: Mohd Anas Shamsi (India), Rajni Kumari (India), Ruhi Sandeep Deshmukh (India), and Vladan Milosevic (Italy). The grants awarded were to provide travel opportunities for the researchers and their teams allowing for information and studies to be exchanged more freely without the burdens of distance. Oncotarget’s editor-in-chief, Mikhail Blagosklonny, states, “The Frontiers in Cancer Science meeting brings together top cancer experts from around the globe and as travel sponsor, Oncotarget is proud to have provided the opportunity for new and groundbreaking research from four international institutions to be shared at the meeting.” By working together, a world-wide problem could find world-wide solutions. Listen to an audio podcast of Oncotarget on Itunes.
Oncotarget uses state of the art submission and manuscript tracking software – https://t.co/LZQlbzuW34
— Oncotarget (@OncotargetJrnl) December 14, 2017